Stroke Research in 2020: Breakthroughs Amid a Global Pandemic
The year 2020 will forever be remembered for the unprecedented global disruption caused by the coronavirus disease 2019 (COVID-19) pandemic. Yet even as healthcare systems worldwide buckled under the strain of surging infections and overwhelmed hospitals, the field of stroke research continued to advance with remarkable resilience. From redefining treatment paradigms to uncovering novel biological mechanisms and integrating artificial intelligence into clinical workflows, 2020 delivered a series of pivotal discoveries that are reshaping how we understand, treat, and prevent stroke.
One of the most sobering revelations of the year came from the Global Burden of Disease (GBD) Study 2019, which confirmed that stroke has climbed from the fifth to the third leading cause of global disease burden over the past three decades. China, in particular, remains a hotspot: with a lifetime stroke risk of nearly 40%—the highest in the world—its population faces a disproportionately heavy burden. Data from the newly released China Stroke Report 2019 underscored the urgency: in 2018 alone, stroke claimed 1.57 million lives in China, accounting for over 22% of all deaths. Rural areas bore a heavier toll than urban centers, with higher incidence and mortality rates pointing to persistent disparities in access to preventive care and acute treatment.
But while the epidemiological picture darkened, therapeutic innovation brightened. A landmark study published in Science by researchers at the University of Copenhagen, led by Maiken Nedergaard and Yuki Mori, overturned long-standing assumptions about post-stroke brain edema. Traditionally viewed as a consequence of blood-brain barrier breakdown and cellular swelling, edema was shown to originate—at least in part—from an unexpected source: cerebrospinal fluid (CSF) influx into the brain parenchyma. Using advanced imaging in mouse models of ischemic stroke, the team demonstrated that early neuronal depolarization waves trigger microvascular constriction, widening perivascular spaces and allowing CSF to flood into brain tissue. Critically, this process was mediated by aquaporin-4 (AQP4), a water channel protein on astrocytic endfeet. When AQP4 was genetically deleted, CSF influx and subsequent swelling were markedly reduced. This discovery not only redefines the pathophysiology of cerebral edema but also opens a new frontier for neuroprotective drug development—targeting the brain’s glymphatic system rather than merely managing symptoms with osmotic agents or steroids.
Parallel to these mechanistic insights, clinical stroke care witnessed transformative progress in reperfusion therapy. Mechanical thrombectomy, already established as standard care in high-income countries since 2015, finally gained validation in resource-limited settings. The RESILIENT trial, conducted across 12 hospitals in Brazil and led by Raul Nogueira’s team, provided the first robust evidence that endovascular thrombectomy significantly improves functional outcomes in low- and middle-income countries (LMICs). Despite systemic challenges—longer transport times, fewer specialized centers, and constrained imaging resources—the trial was halted early due to overwhelming efficacy: patients receiving thrombectomy were more than twice as likely to achieve favorable outcomes at 90 days compared to those receiving standard medical therapy alone. This study shattered the notion that advanced stroke interventions are only viable in wealthy nations and laid the groundwork for global equity in stroke care.
Meanwhile, a fierce debate ignited over whether intravenous thrombolysis with alteplase should precede thrombectomy—a strategy known as “bridging”—or whether patients should proceed directly to mechanical clot retrieval. The DIRECT-MT trial, spearheaded by Jianmin Liu from Changhai Hospital in Shanghai, enrolled 656 patients across 41 Chinese centers and found that direct thrombectomy was non-inferior to bridging therapy in terms of 90-day functional outcomes. While this result electrified the neurointerventional community, subsequent analyses—including a meta-analysis published in Stroke in early 2021—cautioned against abandoning bridging altogether. The data suggested that bridging still conferred higher recanalization rates and lower mortality, especially when newer thrombolytics like tenecteplase (TNK) were used. This nuance highlighted a critical point: the question may not be “bridging versus direct,” but rather “which thrombolytic, at what dose, and for which patients?”
Speaking of tenecteplase, 2020 solidified its position as the next-generation thrombolytic agent. Building on the promising results of the EXTEND-IA TNK trial, which showed TNK outperformed alteplase in achieving early reperfusion before thrombectomy, the follow-up EXTEND-IA TNK 2 trial sought to determine the optimal dose. Led by Bruce Campbell’s group at the Royal Melbourne Hospital, the study compared 0.25 mg/kg versus 0.4 mg/kg TNK in 300 patients with large-vessel occlusion. Surprisingly, both doses yielded identical rates of complete reperfusion and functional independence at 90 days, with no significant differences in safety. The findings effectively settled the dosing debate in favor of the lower, 0.25 mg/kg regimen—simplifying protocols and reducing costs without sacrificing efficacy. In China, multiple phase III trials are now underway to evaluate TNK as a standalone thrombolytic and in extended time windows up to 24 hours, guided by AI-powered perfusion imaging.
This brings us to another paradigm shift: the move from rigid time-based windows to physiology-driven “tissue windows.” The WAKE-UP, EXTEND, THAWS, and ECASS-4 trials collectively demonstrated that patients with unknown onset times—such as those who wake up with stroke symptoms—can still benefit from thrombolysis if advanced imaging reveals a mismatch between the irreversibly damaged core and the salvageable penumbra. A pivotal meta-analysis published in The Lancet in 2020, pooling individual patient data from these four studies, confirmed that alteplase increased the odds of excellent functional outcome by nearly 50%, despite a modest increase in symptomatic intracranial hemorrhage and 90-day mortality. The net benefit, however, was clear. This evidence has now been incorporated into major guidelines, enabling clinicians to treat previously ineligible patients based on what the brain shows—not just when symptoms began.
Neuroprotection, long considered a graveyard of failed clinical trials, also showed signs of revival. The ESCAPE-NA1 trial tested nerinetide (NA-1), a peptide inhibitor of the postsynaptic density protein-95 (PSD-95), in over 1,100 patients undergoing thrombectomy. While the overall results were neutral, a striking subgroup analysis revealed that NA-1 significantly improved outcomes in patients who did not receive alteplase. The reason? Alteplase’s enzymatic activity appears to degrade NA-1, nullifying its effect. This interaction not only explains past failures of neuroprotectants in thrombolysis-era trials but also suggests a new strategy: pairing neuroprotective agents with direct thrombectomy. A follow-up study, REPERFUSE-NA1, is now underway to validate this approach using MRI-based infarct volume as the primary endpoint.
In parallel, China’s own neuroprotective innovation reached a milestone with the approval of edaravone dexborneol (brand name: Xian Bi Xin) by the National Medical Products Administration in July 2020. This combination drug merges a free radical scavenger (edaravone) with an anti-inflammatory agent (dexborneol), targeting multiple injury pathways simultaneously—a principle championed by the Stroke Treatment Academic Industry Roundtable (STAIR) consortium. Although its pivotal trial lacked a reperfusion therapy arm, contradicting STAIR’s recommendation that neuroprotection must be tested alongside recanalization, the drug’s market approval reflects growing confidence in multi-target approaches.
On the secondary prevention front, dual antiplatelet therapy entered a new era. Following the success of the CHANCE trial—which established 21-day clopidogrel-aspirin combination as superior to aspirin alone in high-risk, non-disabling strokes—the THALES trial expanded the evidence base to include ticagrelor. Enrolling over 11,000 patients globally, THALES showed that ticagrelor plus aspirin reduced the 30-day risk of stroke or death by 17% compared to aspirin alone. However, this benefit came at a cost: a nearly four-fold increase in severe bleeding, including fatal intracranial hemorrhage. The trade-off underscores the need for careful patient selection—particularly in populations with high bleeding risk—and highlights ticagrelor’s advantage in patients with CYP2C19 loss-of-function alleles, who metabolize clopidogrel poorly. In China, where over half the population carries these variants, ticagrelor could offer a genetically tailored alternative, pending regulatory approval.
Artificial intelligence (AI) emerged as a silent but powerful enabler across all these domains. From automated detection of large-vessel occlusions on CT angiography to real-time prediction of edema progression and hemorrhagic transformation, AI tools from companies like RapidAI, Brainomix, and Aidoc are becoming integral to stroke workflows. Recognizing the risks of unvalidated algorithms, the scientific community responded with two landmark guidelines in 2020: SPIRIT-AI and CONSORT-AI, published in Nature Medicine. These frameworks set rigorous standards for designing and reporting AI clinical trials, ensuring that digital innovations undergo the same scrutiny as pharmaceuticals. The National Clinical Research Center for Neurological Diseases in Beijing, a leader in this space, has embraced these principles, developing AI platforms that integrate multimodal data—from imaging to genomics—to guide personalized treatment decisions.
Of course, no review of 2020 would be complete without acknowledging the profound impact of COVID-19. Stroke admissions plummeted by up to 50% in some regions, as patients avoided hospitals for fear of infection and healthcare systems diverted resources to pandemic response. Door-to-needle times for thrombolysis lengthened by nearly half an hour in Wuhan; imaging-to-groin puncture delays increased in France. Yet the crisis also accelerated telestroke adoption, with the American Heart Association issuing emergency guidance to support remote consultations. More alarmingly, emerging evidence linked SARS-CoV-2 infection to an elevated risk of stroke—likely due to its prothrombotic and microvascular effects—with worse outcomes among infected patients. Whether the virus directly invades the nervous system or triggers stroke through systemic inflammation remains under investigation, but the association is now undeniable.
As the dust settles on a tumultuous year, the stroke community can take pride in its perseverance. From the glymphatic system to global thrombectomy equity, from tissue-based selection to AI-augmented decision-making, 2020 laid the foundation for a more precise, personalized, and equitable era of stroke care. The challenges ahead—implementing these advances in diverse healthcare settings, training the next generation of clinical researchers, and ensuring that innovation benefits all patients, not just a privileged few—remain formidable. But the momentum is undeniable.
Authors: Yongjun Wang, Yunyun Xiong, Jialei Yang, Guangshuo Li, Ran Yan, Wenjie Wang, Jiaxu Weng, Yiyi Shangguan
Affiliations:
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Beijing Institute for Brain Disorders, Beijing, China
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
Journal: Chinese Stroke Journal, February 2021, Volume 16, Issue 2, Pages 101–117
DOI: 10.3969/j.issn.1673-5765.2021.02.001